November 9, 2017 08:48 AM EST
Financing

Prep­ping PhI­II for Soliris ri­val, Apel­lis rides a bois­ter­ous mar­ket to a $150M IPO

John Carroll

Editor & Founder

The sec­ond time proved the charm for Apel­lis Phar­ma­ceu­ti­cals’ IPO plans. The Ken­tucky biotech, which has been rack­ing up ven­ture cash and pos­i­tive da­ta, priced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times